# Systemic anti-cancer therapy for advanced non-small-cell lung cancer

## Non-squamous non-small cell lung cancer, NTRK fusion positive, PD‑L1 50% or higher

Initial recommended treatment options are:

* the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683) or
* the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or
* the [NICE technology appraisal guidance on atezolizumab](https://www.nice.org.uk/guidance/ta705).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab and pemetrexed and platinum chemotherapy](https://www.nice.org.uk/guidance/ta683), and who have disease progression after follow-up treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).

For people who have disease progression after initial treatment in line with the [NICE technology appraisal guidance on pembrolizumab](https://www.nice.org.uk/guidance/ta531) or [atezolizumab](https://www.nice.org.uk/guidance/ta705), recommended treatment options (NHS England policy) are:

* platinum doublet therapy or
* the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181) or
* pemetrexed and carboplatin.

For maintenance treatment for people who have had treatment with platinum doublet chemotherapy, the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta190).

For maintenance treatment for people who have had treatment in line with the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), the only recommended treatment option is the [NICE technology appraisal guidance on pemetrexed maintenance](https://www.nice.org.uk/guidance/ta402).

Pemetrexed maintenance is a recommended maintenance treatment option for people who have had treatment with pemetrexed and carboplatin (NHS England policy).

For people who have disease progression after treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, recommended treatment options are:

* docetaxel or
* the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347) (NHS England policy).

For people who have had treatment with platinum doublet chemotherapy, the [NICE technology appraisal guidance on pemetrexed and cisplatin](https://www.nice.org.uk/guidance/TA181), pemetrexed and carboplatin, or after pemetrexed maintenance, and who have disease progression after follow-up treatment with docetaxel or in line with the [NICE technology appraisal guidance on docetaxel and nintedanib](https://www.nice.org.uk/guidance/ta347), recommended treatment options (available through the Cancer Drugs Fund) are:

* the [NICE technology appraisal guidance on entrectinib](https://www.nice.org.uk/guidance/ta644) or
* the [NICE technology appraisal guidance on larotrectinib](https://www.nice.org.uk/guidance/ta630).